Claro Advisors’s Pacira BioSciences PCRX Stock Holding History

Claro Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-100	Closed	-$5K	–	717
2018 Q4	$5K	Buy	+100	New	+$4.67K	﹤0.01%	790

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Claro Advisors's PCRX Position: Q1 2019 in Review

Claro Advisors sold out of Pacira BioSciences (PCRX) in Q1 2019, closing a stake of 100 shares — an estimated $5K sold.

Claro Advisors first reported a position in PCRX in Q4 2018 and held it in 1 quarter. The position peaked at $5K in Q4 2018. 210 funds tracked by Wall St. Rank hold PCRX as of Q1 2019.

Claro Advisors reported no remaining Pacira BioSciences position as of Q1 2019 after selling out during the quarter.
Claro Advisors sold 100 Pacira BioSciences shares in Q1 2019, an estimated $5K.
Claro Advisors first reported a position in Pacira BioSciences in Q4 2018 and held it in 1 quarter.
Claro Advisors's Pacira BioSciences position peaked at $5K in Q4 2018.
210 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2019.

Based on Claro Advisors's 13F filing for Q1 2019, filed 10 May 2019.